These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23203823)

  • 1. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.
    Hartmann N; Messmann JJ; Leithäuser F; Weiswange M; Kluge M; Fricke H; Debatin KM; Strauss G
    Blood; 2013 Jan; 121(3):556-65. PubMed ID: 23203823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
    Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
    Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.
    Hartmann N; Leithäuser F; Albers C; Duyster J; Möller P; Debatin KM; Strauss G
    Leukemia; 2011 May; 25(5):848-55. PubMed ID: 21331071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.
    Graubert TA; DiPersio JF; Russell JH; Ley TJ
    J Clin Invest; 1997 Aug; 100(4):904-11. PubMed ID: 9259590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
    Baker MB; Altman NH; Podack ER; Levy RB
    J Exp Med; 1996 Jun; 183(6):2645-56. PubMed ID: 8676085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
    Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
    Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
    Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
    Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
    Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
    Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
    Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
    Hartwig UF; Robbers M; Wickenhauser C; Huber C
    Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
    Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.